193 related articles for article (PubMed ID: 21609747)
1. Archaeosomes with encapsulated antigens for oral vaccine delivery.
Li Z; Zhang L; Sun W; Ding Q; Hou Y; Xu Y
Vaccine; 2011 Jul; 29(32):5260-6. PubMed ID: 21609747
[TBL] [Abstract][Full Text] [Related]
2. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
3. Investigation of archaeosomes as carriers for oral delivery of peptides.
Li Z; Chen J; Sun W; Xu Y
Biochem Biophys Res Commun; 2010 Apr; 394(2):412-7. PubMed ID: 20226174
[TBL] [Abstract][Full Text] [Related]
4. Ovalbumin encapsulation into liposomes results in distinct degrees of oral immunization in mice.
Alves AC; Ramaldes GA; Oliveira MC; Cardoso VN; Mota-Santos TA; Faria AM; Gontijo CM
Cell Immunol; 2008; 254(1):63-73. PubMed ID: 18707680
[TBL] [Abstract][Full Text] [Related]
5. Sperm membrane lipid liposomes can evoke an effective immune response against encapsulated antigen in BALB/c mice.
Atif SM; Salam N; Ahmad N; Hasan IM; Jamal HS; Sudhanshu A; Azevedo V; Owais M
Vaccine; 2008 Oct; 26(46):5874-82. PubMed ID: 18789993
[TBL] [Abstract][Full Text] [Related]
6. Archaeal lipid mucosal vaccine adjuvant and delivery system.
Patel GB; Chen W
Expert Rev Vaccines; 2010 Apr; 9(4):431-40. PubMed ID: 20370552
[TBL] [Abstract][Full Text] [Related]
7. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
Krishnan L; Sad S; Patel GB; Sprott GD
Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
[TBL] [Abstract][Full Text] [Related]
8. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
9. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
10. Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity.
McCluskie MJ; Deschatelets L; Krishnan L
Hum Vaccin Immunother; 2017 Dec; 13(12):2772-2779. PubMed ID: 28537465
[TBL] [Abstract][Full Text] [Related]
11. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.
Akache B; Stark FC; Jia Y; Deschatelets L; Dudani R; Harrison BA; Agbayani G; Williams D; Jamshidi MP; Krishnan L; McCluskie MJ
PLoS One; 2018; 13(12):e0208067. PubMed ID: 30513093
[TBL] [Abstract][Full Text] [Related]
12. Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses.
Sprott GD; Dicaire CJ; Gurnani K; Deschatelets LA; Krishnan L
Vaccine; 2004 Jun; 22(17-18):2154-62. PubMed ID: 15149772
[TBL] [Abstract][Full Text] [Related]
13. M-cell targeted polymeric lipid nanoparticles containing a Toll-like receptor agonist to boost oral immunity.
Ma T; Wang L; Yang T; Ma G; Wang S
Int J Pharm; 2014 Oct; 473(1-2):296-303. PubMed ID: 24984067
[TBL] [Abstract][Full Text] [Related]
14. A novel vaccine delivery system using immunopotentiating fusogenic liposomes.
Hayashi A; Nakanishi T; Kunisawa J; Kondoh M; Imazu S; Tsutsumi Y; Tanaka K; Fujiwara H; Hamaoka T; Mayumi T
Biochem Biophys Res Commun; 1999 Aug; 261(3):824-8. PubMed ID: 10441509
[TBL] [Abstract][Full Text] [Related]
15. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response.
Brgles M; Habjanec L; Halassy B; Tomasić J
Vaccine; 2009 Sep; 27(40):5435-42. PubMed ID: 19632317
[TBL] [Abstract][Full Text] [Related]
16. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
17. β-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination.
De Smet R; Demoor T; Verschuere S; Dullaers M; Ostroff GR; Leclercq G; Allais L; Pilette C; Dierendonck M; De Geest BG; Cuvelier CA
J Control Release; 2013 Dec; 172(3):671-8. PubMed ID: 24041710
[TBL] [Abstract][Full Text] [Related]
18. Safety of archaeosome adjuvants evaluated in a mouse model.
Patel GB; Omri A; Deschatelets L; Sprott GD
J Liposome Res; 2002 Nov; 12(4):353-72. PubMed ID: 12519630
[TBL] [Abstract][Full Text] [Related]
19. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
[TBL] [Abstract][Full Text] [Related]
20. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies.
Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
Int J Pharm; 2013 Jan; 441(1-2):636-42. PubMed ID: 23117021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
